Pfizer’s Chantix May Be Tied to Added Heart Risk, FDA Says
This article is for subscribers only.
Pfizer Inc.’s smoking cessation aid Chantix, already carrying a warning it raises risks of suicide, may be tied to higher heart danger in patients with cardiovascular disease, U.S. regulators said.
The Food and Drug Administration found infrequent chest pain, heart attacks and other adverse reactions in a study of 700 people with cardiovascular disease, the agency said today in a statement. The information will be added to the warnings and precautions section of the prescribing information for Chantix.